A new drug may be the answer to opioid addiction

Health officials say a new drug that they say could help control an epidemic of opioid-related deaths could be on the horizon soon.

Dr. Mark W. Smith, chief of the department of emergency medicine at Washington Hospital Center, says the opioid-based drug, buprenorphine, could be the first of its kind in the United States.

“We have the largest supply of the drug in the world.

There is no reason why it shouldn’t be available in the next 10 to 20 years,” Smith said.”

It’s a new generation of medicine, and it’s not in the pipeline.”

The drug, called buprel, was developed by a group of researchers led by W.H.O. researcher Dr. Mark Smith and is the first opioid-specific drug approved by the Food and Drug Administration.

It was approved for the treatment of severe pain and chronic pain in November and was licensed by the U.S. for other uses in January.

“If we can take a small step forward with this drug, we have the opportunity to address a critical epidemic,” said Dr. Mary Beth Lutz, director of the National Center for Chronic Pain, an advocacy group for people with chronic pain.

Buprel was approved in March by the Drug Enforcement Administration as a replacement for the opioids fentanyl and hydrocodone, which were under federal scrutiny when President Donald Trump took office.

It has not been approved by other countries.

Bucrel’s manufacturer, Pfizer, has said the drug has the potential to lower the death rate from the drug.

Smith said the company hopes to get buprent to market in 2018 or 2019, which would be two years earlier than initially planned.

Smith and other experts have called the drug’s effectiveness in the treatment and recovery of opioid addiction an exciting development.

But it is still early days.

The Food and Drugs Administration has not yet made a decision on whether to allow it to be licensed by another country.

And because bupresto is still in Phase III clinical trials, Smith said it could take a few more years before the drug is on the market.

Smith called the opioid epidemic a national emergency.

“I’m concerned that the crisis is going to continue, and that it’s going to become a national epidemic,” he said.

“If we don’t act now, we’re going to see a huge spike in deaths.”

Smith, who is also president of the American Pain Society, said the pharmaceutical industry has been “working tirelessly” to develop bupreso for years, but that it would take time for other companies to make the drugs available.

“The drug industry has a tremendous amount of experience,” he told the AP.

“It’s just been a little bit slower to get it out to the market, so it’s very important to have that drug available.”

In addition to W.W.O., the AP also spoke with Dr. Matthew D. Rees, president of Medscape Pharmaceuticals, which is a subsidiary of AstraZeneca.

Reis told the Associated Press the company plans to begin clinical trials for buprellas next year.BUPREL is a synthetic opioid derived from fentanyl.

It works by increasing a chemical messenger called acetylcholine in the brain.

Injection of the medication into the bloodstream increases the levels of acetyl choline.

The drug is prescribed for pain from severe back pain and back surgery and is a safe and effective treatment for patients with other serious conditions.